Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.
2.

Long-term effects of weight-reducing drugs in people with hypertension.

Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T.

Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4. Review.

PMID:
26934640
3.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
4.

Long-term effects of weight-reducing drugs in hypertensive patients.

Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich AK, Matyas E, Pignitter N, Siering U.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007654. doi: 10.1002/14651858.CD007654.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD007654.

PMID:
19588440
5.

Long-term effects of weight-reducing drugs in hypertensive patients.

Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007654. doi: 10.1002/14651858.CD007654.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD007654.

PMID:
23543553
6.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
7.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
8.

[Drug treatment of obesity].

Svendsen OL, Toubro S, Breum L, Bruun JM, Astrup AV.

Ugeskr Laeger. 2006 Jan 9;168(2):163-7. Review. Danish.

PMID:
16403342
9.

Orlistat and sibutramine beyond weight loss.

Mannucci E, Dicembrini I, Rotella F, Rotella CM.

Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):342-8. Epub 2007 Oct 24.

PMID:
17928208
10.

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.

Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M.

Obes Rev. 2009 Sep;10(5):564-75. doi: 10.1111/j.1467-789X.2009.00581.x. Epub 2009 May 12. Erratum in: Obes Rev. 2009 Sep;10(5):586.

PMID:
19460116
11.

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.

García Díaz E, Martín Folgueras T.

Nutr Hosp. 2011 May-Jun;26(3):451-7. doi: 10.1590/S0212-16112011000300004. Review.

12.

[Pharmacotherapy in the treatment of obesity].

Hamann A.

MMW Fortschr Med. 2006 Mar 2;148(9):36-8. Review. German.

PMID:
16566392
13.

What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M, Abrams K, Cooper N, Davies M, Khunti K, Sutton A.

Health Technol Assess. 2012;16(5):iii-xiv, 1-195. doi: 10.3310/hta16050. Review.

14.

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.

Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.

Diabetes Obes Metab. 2005 Jan;7(1):47-55.

PMID:
15642075
15.

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.

Johansson K, Sundström J, Neovius K, Rössner S, Neovius M.

Obes Rev. 2010 Nov;11(11):777-91. doi: 10.1111/j.1467-789X.2009.00693.x. Review.

PMID:
20025693
16.

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

Padwal RS, Majumdar SR.

Lancet. 2007 Jan 6;369(9555):71-7. Review.

PMID:
17208644
17.

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.

Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N.

Diabetes Obes Metab. 2002 Jan;4(1):49-55.

PMID:
11874442
18.

Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.

Viner RM, Hsia Y, Tomsic T, Wong IC.

Obes Rev. 2010 Aug;11(8):593-602. doi: 10.1111/j.1467-789X.2009.00651.x. Epub 2009 Nov 17. Review.

PMID:
19922432
19.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
20.

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.

McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K; Sibutramine in Hypertensives Clinical Study Group..

J Hum Hypertens. 2002 Jan;16(1):5-11.

Supplemental Content

Support Center